• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.

作者信息

Şendur Mehmet Ali Nahit, Aksoy Sercan, Akıncı Muhammed Bülent, Ozdemir Nuriye, Dede Didem Şener, Altundag Kadri, Zengin Nurullah, Yalçın Bülent

机构信息

Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, 06100 Sihhiye, Ankara, Turkey.

出版信息

Future Oncol. 2015;11(6):905-7. doi: 10.2217/fon.15.6.

DOI:10.2217/fon.15.6
PMID:25760972
Abstract
摘要

相似文献

1
Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
Future Oncol. 2015;11(6):905-7. doi: 10.2217/fon.15.6.
2
Exemestane in postmenopausal women with early or advanced breast cancer: a review.依西美坦治疗绝经后早期或晚期乳腺癌女性：综述
Expert Opin Pharmacother. 2010 Aug;11(11):1933-42. doi: 10.1517/14656566.2010.495945.
3
Intergroup Exemestane Study mature analysis: overall survival data.国际依西美坦研究成熟分析：总生存数据
Anticancer Drugs. 2008 Feb;19 Suppl 1:S3-7. doi: 10.1097/01.cad.0000277608.23376.bc.
4
Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.芳香化酶抑制剂联合卵巢抑制作为绝经前乳腺癌女性的辅助治疗。
Cancer Biol Ther. 2014;15(12):1586-7. doi: 10.4161/15384047.2014.972783.
5
Are SOFT and TEXT results practice changing and how?SOFT和TEXT的结果是否会改变实践，以及如何改变？
Breast. 2016 Jun;27:122-5. doi: 10.1016/j.breast.2016.02.008. Epub 2016 Apr 22.
6
[ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
Tumori. 2006 Jul-Aug;92(4):suppl 1-9.
7
Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Breast Cancer Res Treat. 2009 Feb;113(3):491-9. doi: 10.1007/s10549-008-9949-9. Epub 2008 Mar 11.
8
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.在接受过非甾体芳香化酶抑制剂治疗的激素受体阳性晚期绝经后乳腺癌女性中，氟维司群与依西美坦对比的双盲、随机、安慰剂对照试验：EFECT研究结果
J Clin Oncol. 2008 Apr 1;26(10):1664-70. doi: 10.1200/JCO.2007.13.5822. Epub 2008 Mar 3.
9
Drug safety evaluation of exemestane.依西美坦的药物安全性评价。
Expert Opin Drug Saf. 2011 May;10(3):473-87. doi: 10.1517/14740338.2011.567264. Epub 2011 Mar 24.
10
The evolving role of exemestane in the management of breast cancer.
Br J Hosp Med (Lond). 2006 Aug;67(8):427-30. doi: 10.12968/hmed.2006.67.8.21978.

引用本文的文献

1
Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.芳香化酶抑制剂在绝经前乳腺癌女性中的应用：现状与未来展望。
Curr Oncol. 2018 Apr;25(2):e168-e175. doi: 10.3747/co.25.3735. Epub 2018 Apr 30.